0001104659-23-073872.txt : 20230622 0001104659-23-073872.hdr.sgml : 20230622 20230622182324 ACCESSION NUMBER: 0001104659-23-073872 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230620 FILED AS OF DATE: 20230622 DATE AS OF CHANGE: 20230622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dudley Robert Michael CENTRAL INDEX KEY: 0001854161 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40363 FILM NUMBER: 231034488 MAIL ADDRESS: STREET 1: C/O TRANSCODE THERAPEUTICS STREET 2: 6 LIBERTY SQUARE #2382 CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Transcode Therapeutics, Inc. CENTRAL INDEX KEY: 0001829635 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811065054 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-301-6857 MAIL ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 4 1 tm2319496-1_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-06-20 0 0001829635 Transcode Therapeutics, Inc. RNAZ 0001854161 Dudley Robert Michael C/O TRANSCODE THERAPEUTICS, INC. 6 LIBERTY SQUARE, #2382 BOSTON MA 02109 1 1 0 0 Chief Executive Officer 0 Common Stock 2023-06-20 4 P 0 6607 2.5498 A 70262 D Common Stock 2023-06-21 4 P 0 12000 2.6515 A 82262 D Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price. Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price. /s/ Thomas A. Fitzgerald, as Attorney-in-Fact 2023-06-22